TherapeuticsMD Inc’s filing revealed that its Director Collins Cooper C. acquired Company’s shares for reported $7099.0 on Aug 22 ’24. In the deal valued at $1.73 per share,4,094 shares were bought. As a result of this transaction, Collins Cooper C. now holds 52,016 shares worth roughly $67620.8.
Then, Collins Cooper C. bought 1,200 shares, generating $2,039 in total proceeds. Upon buying the shares at $1.70, the Director now owns 47,922 shares.
Jefferies downgraded its TherapeuticsMD Inc [TXMD] rating to an Underperform from a a Hold in a research note published recently. A number of analysts have revised their coverage, including JP Morgan’s analysts, who decreased its forecast for the stock in mid May from “an Overweight” to “a Neutral”. Guggenheim began covering TXMD with “Buy” recommendation on December 02, 2019. H.C. Wainwright started covering the stock on October 17, 2019. It rated TXMD as “a Buy”.
Price Performance Review of TXMD
On Friday, TherapeuticsMD Inc [NASDAQ:TXMD] saw its stock jump 28.71% to $1.30. Over the last five days, the stock has gained 26.21%. TherapeuticsMD Inc shares have risen nearly 51.16% since the year began. Nevertheless, the stocks have fallen -42.73% over the past one year. While a 52-week high of $2.75 was reached on 01/03/25, a 52-week low of $0.70 was recorded on 01/02/25. SMA at 50 days reached $1.1075, while 200 days put it at $1.5788.
Levels Of Support And Resistance For TXMD Stock
The 24-hour chart illustrates a support level at 0.9967, which if violated will result in even more drops to 0.6933. On the upside, there is a resistance level at 1.6317. A further resistance level may holdings at 1.9633. The Relative Strength Index (RSI) on the 14-day chart is 68.46, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.0743, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 50.70%. Stochastics %K at 34.94% indicates the stock is a holding.
